Streetbeat News

RNXT

RenovoRx, Inc.

https://renovorx.com

Industry

Biotechnology

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Open

1.10

Mkt cap

27M

Volume

27K

High

1.13

P/E Ratio

-1.88

52-wk high

2.35

Low

1.04

Div yield

N/A

52-wk low

0.53

The article highlights the performance of 12 health care stocks during Wednesday's after-market session. Notable gainers include Holdco Nuvo Group DG (NASDAQ:NUVO) with a 21.5% increase and Entero Therapeutics (NASDAQ:ENTO) with an 8.69% rise. Significant losers include Assure Holdings (NASDAQ:IONM) which fell by 38.4% and RenovoRx (NASDAQ:RNXT) which declined by 10.26%.

Portfolio Pulse from Benzinga Insights

June 12, 2024 | 8:31 pm

RenovoRx's CEO updated shareholders on the company's progress in Q1 2024, highlighting significant milestones, including $17.2 million raised, advancements in the Phase III TIGeR-PaC clinical trial, and the expansion of their TAMP therapy platform. Key management promotions and supportive research publications were also noted.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:42 pm

RenovoRx (NASDAQ: RNXT) announced the publication of pre-clinical studies that support the efficacy and drug delivery mechanism of its TAMP therapy platform. The studies show that TAMP increases intra-arterial pressure, leading to a 100-fold increase in local tissue concentration of the therapy, potentially improving efficacy, safety, and widening the therapeutic window of drugs. The data was published in the Journal of Vascular Interventional Radiology.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:36 pm

RenovoRx, identified by its ticker RNXT, has successfully regained compliance with Nasdaq's listing requirements. This development is crucial for the company's continued listing on the exchange and may positively influence investor confidence and the stock's market performance.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 12:35 pm

RenovoRx has finalized a subscription agreement with accredited investors for an $11.1M private placement at market price, extending its cash runway into 2026. This financing will support the Phase III TIGeR-PaC trial and expand the TAMP clinical development pipeline into more cancer indications.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:36 pm

Alliance Global Partners analyst Scott Henry initiated coverage on RenovoRx (NASDAQ:RNXT) with a Buy rating and set a price target of $4.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 1:04 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Sonoma Pharmaceuticals (SNOA) led the gainers with a 36.0% increase, while Evaxion Biotech (EVAX) saw the largest decline among the losers, dropping 33.1%. Other notable movers included 2seventy bio (TSVT), Vaxart (VXRT), and Trinity Biotech (TRIB) with substantial gains, and SINTX Techs (SINT), Owlet (OWLT), and NexImmune (NEXI) with notable losses.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 5:31 pm

Health care stocks experienced significant movement in Wednesday's intraday session. Sana Biotechnology (SANA) led the gainers with a 45.2% increase, while DocGo (DCGO) saw the largest decline among the losers, dropping 35.2%. Other notable movers included Amarin Corp (AMRN), Vicarious Surgical (RBOT), and TG Therapeutics (TGTX). Market capitalizations were also highlighted, indicating the size of each company.

Portfolio Pulse from Benzinga Insights

January 10, 2024 | 5:31 pm

Longboard Pharmaceuticals, Inc. (LBPH) shares soared by approximately 200% after announcing positive topline data from their PACIFIC Phase 1b/2a study of bexicaserin (LP352) for seizures associated with Developmental and Epileptic Encephalopathies (DEEs). Other stocks experienced significant movement in Tuesday's mid-day session, with various companies seeing substantial gains or losses.

Portfolio Pulse from Avi Kapoor

January 02, 2024 | 6:35 pm

In Tuesday's intraday session, several healthcare stocks experienced significant movements. Longboard Pharmaceuticals (LBPH) saw a 200.7% increase, while NGM Biopharmaceuticals (NGM) rose by 49.01%. Cardio Diagnostics Hldgs (CDIO) increased by 37.27%, SenesTech (SNES) by 33.07%, Cue Health (HLTH) by 29.29%, and VolitionRX (VNRX) by 27.32%. Conversely, Anavex Life Sciences (AVXL) fell by 34.5%, China SXT Pharmaceuticals (SXTC) by 29.98%, Corcept Therapeutics (CORT) by 28.19%, LumiraDx (LMDX) by 25.6%, RenovoRx (RNXT) by 24.9%, and Aditxt (ADTX) by 23.08%.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.